193 related articles for article (PubMed ID: 9627667)
1. Antineoplastic agents 365. Dolastatin 10 SAR probes.
Pettit GR; Srirangam JK; Barkoczy J; Williams MD; Boyd MR; Hamel E; Pettit RK; Hogan F; Bai R; Chapuis JC; McAllister SC; Schmidt JM
Anticancer Drug Des; 1998 Jun; 13(4):243-77. PubMed ID: 9627667
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and X-ray crystal structure of the dolabellaauricularia peptide dolastatin 18.
Pettit GR; Hogan F; Herald DL
J Org Chem; 2004 Jun; 69(12):4019-22. PubMed ID: 15176826
[TBL] [Abstract][Full Text] [Related]
3. Antineoplastic agents 360. Synthesis and cancer cell growth inhibitory studies of dolastatin 15 structural modifications.
Pettit GR; Flahive EJ; Boyd MR; Bai R; Hamel E; Pettit RK; Schmidt JM
Anticancer Drug Des; 1998 Jan; 13(1):47-66. PubMed ID: 9474242
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological activity of chimeric structures derived from the cytotoxic natural compounds dolastatin 10 and dolastatin 15.
Poncet J; Busquet M; Roux F; Pierré A; Atassi G; Jouin P
J Med Chem; 1998 Apr; 41(9):1524-30. PubMed ID: 9554885
[TBL] [Abstract][Full Text] [Related]
5. Antineoplastic agents. 445. Synthesis and evaluation of structural modifications of (Z)- and (E)-combretastatin A-41.
Pettit GR; Rhodes MR; Herald DL; Hamel E; Schmidt JM; Pettit RK
J Med Chem; 2005 Jun; 48(12):4087-99. PubMed ID: 15943482
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.
Mohammad RM; Varterasian ML; Almatchy VP; Hannoudi GN; Pettit GR; Al-Katib A
Clin Cancer Res; 1998 May; 4(5):1337-43. PubMed ID: 9607595
[TBL] [Abstract][Full Text] [Related]
7. Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications.
Pettit GR; Srirangam JK; Barkoczy J; Williams MD; Durkin KP; Boyd MR; Bai R; Hamel E; Schmidt JM; Chapuis JC
Anticancer Drug Des; 1995 Oct; 10(7):529-44. PubMed ID: 7495477
[TBL] [Abstract][Full Text] [Related]
8. Hybrids of the hemiasterlin analogue taltobulin and the dolastatins are potent antimicrotubule agents.
Zask A; Kaplan J; Musto S; Loganzo F
J Am Chem Soc; 2005 Dec; 127(50):17667-71. PubMed ID: 16351096
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of Dolastatin 15 mimetic peptoids.
Schmitt J; Bernd M; Kutscher B; Kessler H
Bioorg Med Chem Lett; 1998 Feb; 8(4):385-8. PubMed ID: 9871690
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of active isomers, segments, and analogs of dolastatin 10 on ligand interactions with tubulin. Correlation with cytotoxicity.
Bai R; Roach MC; Jayaram SK; Barkoczy J; Pettit GR; Ludueña RF; Hamel E
Biochem Pharmacol; 1993 Apr; 45(7):1503-15. PubMed ID: 8471072
[TBL] [Abstract][Full Text] [Related]
11. Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules.
Bai R; Friedman SJ; Pettit GR; Hamel E
Biochem Pharmacol; 1992 Jun; 43(12):2637-45. PubMed ID: 1632820
[TBL] [Abstract][Full Text] [Related]
12. Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay.
Aherne GW; Hardcastle A; Valenti M; Bryant A; Rogers P; Pettit GR; Srirangam JK; Kelland LR
Cancer Chemother Pharmacol; 1996; 38(3):225-32. PubMed ID: 8646796
[TBL] [Abstract][Full Text] [Related]
13. Sustained intracellular retention of dolastatin 10 causes its potent antimitotic activity.
Verdier-Pinard P; Kepler JA; Pettit GR; Hamel E
Mol Pharmacol; 2000 Jan; 57(1):180-7. PubMed ID: 10617693
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of action of tubulysin, an antimitotic peptide from myxobacteria.
Khalil MW; Sasse F; Lünsdorf H; Elnakady YA; Reichenbach H
Chembiochem; 2006 Apr; 7(4):678-83. PubMed ID: 16491500
[TBL] [Abstract][Full Text] [Related]
15. Isolation and structure of the human cancer cell growth inhibitory cyclodepsipeptide dolastatin 16.
Pettit GR; Xu JP; Hogan F; Williams MD; Doubek DL; Schmidt JM; Cerny RL; Boyd MR
J Nat Prod; 1997 Aug; 60(8):752-4. PubMed ID: 9287413
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity studies with chiral isomers and with segments of the antimitotic marine peptide dolastatin 10.
Bai RL; Pettit GR; Hamel E
Biochem Pharmacol; 1990 Oct; 40(8):1859-64. PubMed ID: 2242019
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and activity of novel analogs of hemiasterlin as inhibitors of tubulin polymerization: modification of the A segment.
Yamashita A; Norton EB; Kaplan JA; Niu C; Loganzo F; Hernandez R; Beyer CF; Annable T; Musto S; Discafani C; Zask A; Ayral-Kaloustian S
Bioorg Med Chem Lett; 2004 Nov; 14(21):5317-22. PubMed ID: 15454219
[TBL] [Abstract][Full Text] [Related]
18. Antineoplastic agents. 515. Synthesis of human cancer cell growth inhibitors derived from 3,4-methylenedioxy-5,4'-dimethoxy-3'-amino-Z-stilbene.
Pettit GR; Anderson CR; Gapud EJ; Jung MK; Knight JC; Hamel E; Pettit RK
J Nat Prod; 2005 Aug; 68(8):1191-7. PubMed ID: 16124759
[TBL] [Abstract][Full Text] [Related]
19. Lyngbyastatin 1 and Ibu-epilyngbyastatin 1: synthesis, stereochemistry, and NMR line broadening.
Bai R; Bates RB; Hamel E; Moore RE; Nakkiew P; Pettit GR; Sufi BA
J Nat Prod; 2002 Dec; 65(12):1824-9. PubMed ID: 12502322
[TBL] [Abstract][Full Text] [Related]
20. Antineoplastic Agents. 510. Isolation and structure of dolastatin 19 from the Gulf of California sea hare Dolabella auricularia.
Pettit GR; Xu JP; Doubek DL; Chapuis JC; Schmidt JM
J Nat Prod; 2004 Aug; 67(8):1252-5. PubMed ID: 15332837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
